Cargando…

Current status of photodynamic technology for urothelial cancer

5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating th...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Keiji, Fukuhara, Hideo, Yamamoto, Shinkuro, Karashima, Takashi, Kurabayashi, Atsushi, Furihata, Mutsuo, Hanazaki, Kazuhiro, Lai, Hung Wei, Ogura, Shun‐Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819295/
https://www.ncbi.nlm.nih.gov/pubmed/34750935
http://dx.doi.org/10.1111/cas.15193
_version_ 1784646029375700992
author Inoue, Keiji
Fukuhara, Hideo
Yamamoto, Shinkuro
Karashima, Takashi
Kurabayashi, Atsushi
Furihata, Mutsuo
Hanazaki, Kazuhiro
Lai, Hung Wei
Ogura, Shun‐Ichiro
author_facet Inoue, Keiji
Fukuhara, Hideo
Yamamoto, Shinkuro
Karashima, Takashi
Kurabayashi, Atsushi
Furihata, Mutsuo
Hanazaki, Kazuhiro
Lai, Hung Wei
Ogura, Shun‐Ichiro
author_sort Inoue, Keiji
collection PubMed
description 5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5‐aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5‐aminolevulinic acid. In addition to these applications in urological cancers, 5‐aminolevulinic acid–based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers.
format Online
Article
Text
id pubmed-8819295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88192952022-02-09 Current status of photodynamic technology for urothelial cancer Inoue, Keiji Fukuhara, Hideo Yamamoto, Shinkuro Karashima, Takashi Kurabayashi, Atsushi Furihata, Mutsuo Hanazaki, Kazuhiro Lai, Hung Wei Ogura, Shun‐Ichiro Cancer Sci Review Articles 5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5‐aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5‐aminolevulinic acid. In addition to these applications in urological cancers, 5‐aminolevulinic acid–based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers. John Wiley and Sons Inc. 2021-12-02 2022-02 /pmc/articles/PMC8819295/ /pubmed/34750935 http://dx.doi.org/10.1111/cas.15193 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Inoue, Keiji
Fukuhara, Hideo
Yamamoto, Shinkuro
Karashima, Takashi
Kurabayashi, Atsushi
Furihata, Mutsuo
Hanazaki, Kazuhiro
Lai, Hung Wei
Ogura, Shun‐Ichiro
Current status of photodynamic technology for urothelial cancer
title Current status of photodynamic technology for urothelial cancer
title_full Current status of photodynamic technology for urothelial cancer
title_fullStr Current status of photodynamic technology for urothelial cancer
title_full_unstemmed Current status of photodynamic technology for urothelial cancer
title_short Current status of photodynamic technology for urothelial cancer
title_sort current status of photodynamic technology for urothelial cancer
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819295/
https://www.ncbi.nlm.nih.gov/pubmed/34750935
http://dx.doi.org/10.1111/cas.15193
work_keys_str_mv AT inouekeiji currentstatusofphotodynamictechnologyforurothelialcancer
AT fukuharahideo currentstatusofphotodynamictechnologyforurothelialcancer
AT yamamotoshinkuro currentstatusofphotodynamictechnologyforurothelialcancer
AT karashimatakashi currentstatusofphotodynamictechnologyforurothelialcancer
AT kurabayashiatsushi currentstatusofphotodynamictechnologyforurothelialcancer
AT furihatamutsuo currentstatusofphotodynamictechnologyforurothelialcancer
AT hanazakikazuhiro currentstatusofphotodynamictechnologyforurothelialcancer
AT laihungwei currentstatusofphotodynamictechnologyforurothelialcancer
AT ogurashunichiro currentstatusofphotodynamictechnologyforurothelialcancer